6/19/2013: Business: SINGH BROTHERS TO SELL 23% STAKE IN RELIGARE

Promoters Malvinder, Shivinder Singh to sell up to 22.75% in Religare to meet RBI norms for bank licences Joel Rebello Malvinder Singh (left) and Shivender Singh. Photo: Hindustan Times Updated: Wed, Jun 19 2013. 12 34 AM IST Mumbai: ...

Daiichi-Sankyo is reportedly considering suing Malvinder Singh and Shivinder Singh for concealing crucial information while selling their stake in Ranbaxy Laboratories to the Japanese company. It is tempting to ask what sort of due diligence the ...

Shivinder Mohan Singh, Salman Khan and Malvinder Mohan Singh On Wednesday, Salman Khan was in the city to flag off the Little Hearts Programme, a joint initiative of Fortis Foundation and Being Human aimed at providing free treatment to children ...

Despite all these denials, Malvinder and Shivinder Singh may be in for a little bit of trouble and the way out is unlikely to be easy. There are chances that Daiichi may indeed go ahead with the legal case.

Malvinder and Shivinder Mohan Singh, promoters of hospital chain Fortis Healthcare and financial services firm Religare, are set to launch a health care-focussed private equity fund making them the second highprofile entrepreneurs to launch such a fund.

Singh will have additional responsibility of overseeing business in Greater China, South Korea, India and Southwest Asia QUICK LINKS: People | Results | Management QUICK LINKS: People | Results | Management Promoters Malvinder, Shivinder ...

The Singh family on Thursday said Daiichi Sankyo's allegation of concealment and misrepresentation regarding drug research at Ranbaxy Laboratories is false and baseless. On Wednesday, Daiichi Sankyo said it is weighing legal options to sue the ...

The golden mahseer fights like hell," says Indrave Singh Mann, 67, an angling enthusiast since he was five years old. This resident of Delhi also happens to hold the record for the biggest trout ever caught in an angling competition, held in ...

Singh brothers might be stopped by 'fit & proper' hurdle due to US drug norm violations; firm says confident of qualifyingThe promoters of Religare Enterprises will face an uphill task in satisfying the ‘fit and proper’ criteria prescribed by the Reserve Bank of India (RBI) for new bank licence applications, due to the various troubles of Ranbaxy, their earlier venture, with the US drug regulator.Religare, which has interests in broking, mutual funds, insurance and financial ...